BACKGROUND INFORMATION ON THE PROCEDURE 
1. 
Submission of the dossier 
The  applicant  Helsinn-Birex  Pharmaceuticals  Ltd.,  submitted  on  29  July  2003  an  application  for 
Marketing  Authorisation  to  the  European  Medicines  Agency  (EMEA)  for  Aloxi,  through  the 
centralised procedure. After agreement by the CHMP on 23 January 2003, this medicinal product has 
been  referred  to  Part  B  of  the  Annex  to  Council  Regulation  No  (EEC)  2309/93  of  22  July  1993  as 
amended. 
The Rapporteur and Co-Rapporteur appointed by the CHMP and the evaluation teams were: 
Rapporteur:  Dr. Salmon 
Co-Rapporteur:  Dr. Calvo Rojas 
Licensing status: 
The product was not licensed in any country at the time of submission of the application. 
2. 
Steps taken for the assessment of the product  
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
The application was received by the EMEA on 29 July 2003.  
The procedure started on 18 August 2003. 
The Rapporteur's first Assessment Report was circulated to all CHMP members on 30 October 
2003. The Co-Rapporteur's first Assessment Report was circulated to all CHMP members on 29 
October 2003. 
During  the  meeting  on  17  December  2003,  the  CHMP  agreed  on  the  consolidated  List  of 
Questions to be sent to the applicant. The final consolidated List of Questions was sent to the 
applicant on 17 December 2003. 
The  applicant  submitted  the  responses  to  the  CHMP  consolidated  List  of  Questions  on 
15 June 2004. 
The Rapporteurs circulated the Joint Assessment Report on the applicant’s responses to the List 
of Questions to all CHMP members on 20 August 2004. 
During the CHMP meeting on 16 September 2004, the CHMP agreed on a List of Outstanding 
Issues to be addressed in writing and/or in an oral explanation by the applicant. 
The  applicant  submitted  written  responses  to  the  CHMP  List  of  Outstanding  Issues  on  15 
October 2004 and asked for an oral explanation to address section 4.1 and 5.1 of the SPC. 
The Rapporteurs circulated the Joint Assessment Report on the applicant’s responses to the List 
of Outstanding Issues to all CHMP members on 28 October 2004. 
During the CHMP meeting on 17 November 2004, outstanding issues on section 4.1 and 5.1 of 
the SPC were addressed by the applicant during an oral explanation. 
During the December 2004 meeting, the CHMP, in the light of the overall data submitted and 
the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for  granting  a 
Marketing  Authorisation  to  Aloxi  on  15  December  2004.  The  applicant  provided  the  letter  of 
undertaking on the follow-up measures to be fulfilled post-authorisation on 14 December 2004. 
The  CHMP  opinions  were  forwarded,  in  all  official  languages  of  the  European  Union,  to  the 
European Commission, which adopted the corresponding Decisions on 22 March 2005. 
 
 
 
 
 
 
 
 
 
 
